Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015

M. Krutova, J. Matejkova, P. Drevinek, EJ. Kuijper, O. Nyc, . ,

. 2017 ; 36 (11) : 2251-2258. [pub] 20170705

Language English Country Germany

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago

The aim of the study was to provide an update on the epidemiology of C. difficile infection (CDI) in a representative number of hospitals within the Czech Republic in 2015. In 2015, twenty-eight Czech hospitals were invited to participate in a CDI study. Laboratories sent the first 20 consecutive C. difficile isolates for characterization by capillary-electrophoresis (CE) ribotyping and the presence of toxin genes and collected patient data on previous hospitalization, antibiotic treatment, the number of CDI episodes and the course of CDI. The mean incidence of CDI was 5.2 [95% CI 4.2-6.2] cases per 10,000 patient-bed days in 27 hospitals in 2015. Of 490 C. difficile isolates, the prevalent PCR ribotypes (RTs) were 001 (n = 164, 33.5%) and 176 (n = 125, 25.5%) followed by 014 (n = 37, 7.6%), 012 (n = 17, 3.5%), 020 (n = 16, 3.3%), 017 (n = 14, 2.9%) and 002 (n = 11, 2.2%). A severe course of CDI was reported in 104 cases (21.2%) with significant association with RT001 infection (p = 0.03). CDI recurrence was 10.8% (n = 53). The previous use of fluoroquinolones was associated with RTs 001 and 176 CDIs (p = 0.046 and p = 0.041). We observed a persistence of RTs 001 and 176 CDIs in the Czech Republic that was associated with the previous use of fluoroquinolones. This highlights the need for a reduction in fluoroquinolone use in Czech hospital settings.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024869
003      
CZ-PrNML
005      
20181211084520.0
007      
ta
008      
180709s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10096-017-3055-z $2 doi
035    __
$a (PubMed)28681203
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Krůtová, Marcela $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic. marcela.krutova@lfmotol.cuni.cz. $7 xx0191653
245    10
$a Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015 / $c M. Krutova, J. Matejkova, P. Drevinek, EJ. Kuijper, O. Nyc, . ,
520    9_
$a The aim of the study was to provide an update on the epidemiology of C. difficile infection (CDI) in a representative number of hospitals within the Czech Republic in 2015. In 2015, twenty-eight Czech hospitals were invited to participate in a CDI study. Laboratories sent the first 20 consecutive C. difficile isolates for characterization by capillary-electrophoresis (CE) ribotyping and the presence of toxin genes and collected patient data on previous hospitalization, antibiotic treatment, the number of CDI episodes and the course of CDI. The mean incidence of CDI was 5.2 [95% CI 4.2-6.2] cases per 10,000 patient-bed days in 27 hospitals in 2015. Of 490 C. difficile isolates, the prevalent PCR ribotypes (RTs) were 001 (n = 164, 33.5%) and 176 (n = 125, 25.5%) followed by 014 (n = 37, 7.6%), 012 (n = 17, 3.5%), 020 (n = 16, 3.3%), 017 (n = 14, 2.9%) and 002 (n = 11, 2.2%). A severe course of CDI was reported in 104 cases (21.2%) with significant association with RT001 infection (p = 0.03). CDI recurrence was 10.8% (n = 53). The previous use of fluoroquinolones was associated with RTs 001 and 176 CDIs (p = 0.046 and p = 0.041). We observed a persistence of RTs 001 and 176 CDIs in the Czech Republic that was associated with the previous use of fluoroquinolones. This highlights the need for a reduction in fluoroquinolone use in Czech hospital settings.
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a Clostridioides difficile $x klasifikace $x genetika $x izolace a purifikace $7 D016360
650    _2
$a infekce spojené se zdravotní péčí $x epidemiologie $x mikrobiologie $7 D003428
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a bakteriální léková rezistence $x fyziologie $7 D024881
650    _2
$a pseudomembranózní enterokolitida $x farmakoterapie $x epidemiologie $x mikrobiologie $7 D004761
650    _2
$a fluorochinolony $x terapeutické užití $7 D024841
650    _2
$a nemocnice $7 D006761
650    _2
$a lidé $7 D006801
650    _2
$a ribotypizace $7 D021521
655    _2
$a časopisecké články $7 D016428
700    1_
$a Matějková, Jana $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic. $7 xx0209775
700    1_
$a Dřevínek, Pavel, $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic. $d 1975- $7 xx0075827
700    1_
$a Kuijper, E J $u Leiden University Medical Centre, Leiden, the Netherlands.
700    1_
$a Nyč, Otakar $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic. $7 uk2007399535
773    0_
$w MED00001612 $t European journal of clinical microbiology & infectious diseases official publication of the European Society of Clinical Microbiology $x 1435-4373 $g Roč. 36, č. 11 (2017), s. 2251-2258
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28681203 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20181211084644 $b ABA008
999    __
$a ok $b bmc $g 1317000 $s 1021790
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 36 $c 11 $d 2251-2258 $e 20170705 $i 1435-4373 $m European journal of clinical microbiology & infectious diseases $n Eur J Clin Microbiol Infect Dis $x MED00001612
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...